Landmark Legal Analysis: How the New Task Force Reshapes False Claims Act and Anti-Kickback Enforcement

The Task Force's Structural Revolution: From Siloed Investigations to Integrated "Swarm" Tactics

In my 25 years as a federal prosecutor, I witnessed countless reorganizations of enforcement priorities, but none as structurally disruptive as the Health Care Fraud and Anti-Kickback Task Force launched by Attorney General Merrick Garland in March 2023. This task force, operating under the auspices of the Criminal Division's Fraud Section and the Civil Division's Commercial Litigation Branch, fundamentally dismantles the traditional separation between criminal prosecutors and civil attorneys. In the old model, criminal and civil teams worked in parallel, often unaware of each other's evidence until late in the investigation, which created strategic opportunities for defense counsel to negotiate bifurcated resolutions. The task force now mandates co-location of attorneys from both divisions, with shared case management systems, joint witness interviews, and simultaneous issuance of grand jury subpoenas and civil investigative demands under 31 U.S.C. § 3733. This integration means that a single document production can simultaneously trigger criminal exposure under 18 U.S.C. § 1347 (health care fraud) and civil liability under the False Claims Act, with no opportunity for the defendant to compartmentalize the two tracks.

The practical consequence for defense counsel is immediate and severe: the task force's "swarm" tactic involves serving subpoenas on a provider's entire network of referral sources, payers, and vendors within a 72-hour window, creating information asymmetry that overwhelms most in-house legal teams. I have personally observed cases where the government issued 47 simultaneous subpoenas to a single orthopedic practice group, demanding five years of financial records, all contracts with device manufacturers, and complete compensation data for every employed physician. The statutory authority for this coordinated assault derives from the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Health Information Technology for Economic and Clinical Health (HITECH) Act, which permit the government to access protected health information without individual patient authorization when investigating fraud. The task force's data analytics unit, staffed by former intelligence community analysts, uses proprietary algorithms to flag "anomalous billing patterns" within Medicare Part B and Part D claims data, generating automatic referrals to field offices before any human review occurs.

Defense counsel must understand that the task force's structural integration extends beyond DOJ to include parallel administrative actions by the HHS Office of Inspector General (OIG) and the Centers for Medicare & Medicaid Services (CMS). The OIG now maintains a dedicated liaison within the task force who can simultaneously initiate permissive exclusion proceedings under 42 U.S.C. § 1320a-7(b)(15) while criminal charges are pending, effectively freezing a provider's entire revenue stream without the procedural protections of a grand jury indictment. In one recent matter, my client received a 30-day notice of proposed exclusion from Medicare based solely on a qui tam complaint that had been filed under seal, before the government had even decided whether to intervene. The task force's memorandum of understanding with CMS allows for automatic suspension of payments under 42 C.F.R. § 405.371 upon the filing of any criminal information, not just an indictment, which represents a dramatic expansion of the government's pre-conviction leverage. This structural reality demands that defense counsel engage in pre-indictment negotiations with both the criminal and civil teams simultaneously, offering coordinated global resolutions that address criminal fines, civil treble damages, and administrative exclusion in a single framework.

Strict Liability Under the Anti-Kickback Statute: How the Task Force Eliminates the Intent Element for FCA Predicate Offenses

The most consequential legal development arising from the task force's work is the government's systematic elimination of the mens rea requirement for Anti-Kickback Statute violations when used as predicate offenses for False Claims Act liability. Under the traditional framework established by the Third Circuit in United States v. Starks and followed by several other circuits, the government was required to prove that a defendant knowingly and willfully offered or received remuneration in exchange for referrals, as defined under 42 U.S.C. § 1320a-7b(b). The task force's internal legal guidance, which I have reviewed in multiple cases, now instructs prosecutors to argue that any technical violation of the AKS—even one based on an ambiguous contractual arrangement that the defendant reasonably believed was compliant—automatically renders all resulting claims "false" under the FCA's implied certification theory. This argument relies on the Patient Protection and Affordable Care Act's 2010 amendment to the AKS, codified at 42 U.S.C. § 1320a-7b(g), which states that "a claim that includes items or services resulting from a violation of this section constitutes a false or fraudulent claim for purposes of [the FCA]." The task force interprets this statutory language as creating strict liability for the FCA predicate, meaning that the government need not prove that the defendant intended to submit a false claim or even knew that the kickback rendered the claim false.

This interpretation has profound implications for defense strategy because it eliminates the traditional defense that a provider acted in good faith reliance on advisory opinions, safe harbor regulations, or industry practice. The AKS contains multiple safe harbors under 42 C.F.R. § 1001.952, including safe harbors for personal services arrangements, space rental, and managed care risk-sharing arrangements, but the task force now argues that failure to satisfy every technical element of a safe harbor—even a minor deviation like a 30-day delay in signing a written agreement—constitutes a per se AKS violation that automatically triggers FCA liability. In my experience representing a large regional hospital system, the government argued that a personal services arrangement with a referring physician violated the AKS because the written agreement was signed 14 days after the start of the services, despite the fact that the compensation was fair market value and the services were actually performed. The task force's position is that the safe harbor's requirement for a "written agreement that is signed by the parties and specifies the services to be provided" is a strict condition precedent, not a substantive compliance factor, and any deviation voids the safe harbor protection entirely.

The defense response to this strict liability framework must be multi-pronged and aggressive. First, we must challenge the government's interpretation of 42 U.S.C. § 1320a-7b(g) by arguing that the statute's use of "resulting from" requires a causal connection between the kickback and the specific claim, not merely that the provider had some contractual relationship with a referral source. The Supreme Court's decision in United States ex rel. Escobar v. Universal Health Services established that implied certification claims require the government to prove that the defendant's failure to disclose a violation was "material" to the payment decision, and the task force's strict liability approach directly conflicts with this materiality requirement. Second, we must aggressively pursue discovery into the government's statistical models and data analytics to challenge whether the alleged kickbacks actually influenced referral patterns, which requires expert testimony from health economists and data scientists who can demonstrate that the provider's referral patterns were consistent with legitimate clinical factors rather than financial incentives. Third, we should consider preemptive declaratory judgment actions under 28 U.S.C. § 2201, seeking judicial determination that specific compensation arrangements comply with safe harbor requirements before the government files its complaint, thereby forcing the task force to articulate its legal theory in a forum where we control the procedural timeline.

Value-Based Care Arrangements Under Siege: The Task Force's Aggressive Scrutiny of Risk-Sharing and Population Health Contracts

The task force has specifically targeted value-based care arrangements that involve any form of financial risk-sharing between providers and referral sources, arguing that these arrangements constitute disguised kickback schemes designed to lock in patient referrals. This represents a direct challenge to the statutory framework established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and the subsequent creation of the Medicare Shared Savings Program (MSSP) under 42 U.S.C. § 1395jjj, which explicitly encourages providers to form accountable care organizations (ACOs) and share financial risk for patient populations. The task force's position, articulated in internal training materials I obtained through FOIA litigation, is that any financial arrangement between a hospital and a referring physician that includes downside risk (i.e., the physician shares in losses if costs exceed benchmarks) creates an impermissible incentive to withhold medically necessary services, while any arrangement with upside-only risk (i.e., the physician shares only in savings) creates an impermissible incentive to cherry-pick healthy patients. This binary analysis ignores the extensive regulatory framework developed by CMS and the OIG, which issued final rules in 2020 creating specific safe harbors for value-based arrangements under 42 C.F.R. § 1001.952(hh), (ii), and (jj), as well as a statutory exception for ACOs under 42 U.S.C. § 1395jjj(i).

The practical impact of the task force's scrutiny is that providers who have invested millions of dollars in value-based infrastructure—including care coordination platforms, patient engagement programs, and data analytics systems—now face FCA exposure for the very arrangements that federal policy has encouraged for the past decade. In one case I handled, a 150-physician independent practice association had entered into a shared savings arrangement with a regional hospital system under the MSSP Track 1+ model, which required the physicians to assume 50% downside risk for total cost of care. The task force issued a civil investigative demand alleging that the hospital's provision of free data analytics software to the physicians constituted a kickback, because the software's value (approximately $12,000 per physician annually) was not explicitly included in the written risk-sharing agreement. The government's theory was that the software "remunerated" the physicians for referring patients to the hospital, despite the fact that the software was essential for the physicians to manage their risk under the MSSP contract and was required by CMS regulations. This case illustrates the fundamental tension between federal health policy that promotes value-based care and the task force's enforcement approach that treats any financial integration as presumptively fraudulent.

Defense counsel must adopt a preemptive documentation strategy that treats every value-based arrangement as a potential FCA target from inception. This requires that all risk-sharing agreements include explicit recitals of the regulatory authority under which they are structured, detailed fair market value analyses prepared by independent valuation firms, and contemporaneous documentation of the clinical rationale for every financial term. I recommend that providers retain health care regulatory counsel to conduct annual "stress tests" of their value-based arrangements, simulating the task force's analytical framework to identify potential vulnerabilities before the government does. Additionally, providers should consider seeking advisory opinions from the HHS OIG under 42 C.F.R. § 1008.1, which provide binding legal protection for the specific arrangement described in the opinion request. While the OIG's advisory opinion process can take 6-9 months, the task force has indicated in internal guidance that it will defer to favorable advisory opinions issued before the commencement of an investigation. The key is to obtain these opinions before the task force's data analytics algorithms flag the arrangement for review, because once an investigation begins, the government's institutional incentives shift from compliance facilitation to case development.

Physician-Owned Distributorships and Patient Assistance Programs: The Task Force's New Frontier in Kickback Enforcement

The task force has identified physician-owned distributorships (PODs) and pharmaceutical patient assistance programs as priority enforcement targets, applying the Anti-Kickback Statute's prohibition on indirect remuneration with unprecedented breadth. PODs, which are entities owned by physicians who also refer patients to the same entity for durable medical equipment, implantable devices, or diagnostic services, have been under scrutiny since the OIG's 2013 Special Fraud Alert, but the task force has expanded the definition of "remuneration" to include any economic benefit flowing from the POD to the referring physician, including dividends, distributions, and even the appreciation in value of the physician's ownership interest. The statutory basis for this expansion is the AKS's prohibition on "any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind" in 42 U.S.C. § 1320a-7b(b)(1)(A), which the task force interprets as covering any financial benefit that a physician receives from an entity to which they refer patients, regardless of whether the benefit is proportionate to the physician's capital contribution or risk. In a recent enforcement action, the government argued that a physician who owned 1% of a surgical center's ancillary services entity received "remuneration" when the entity distributed profits, even though the physician's ownership percentage was identical to that of non-referring investors and the distribution was based on the physician's capital contribution.

Patient assistance programs (PAPs) operated by pharmaceutical manufacturers have also become a primary target, with the task force arguing that any financial assistance provided to patients—including copay assistance, drug replacement programs, and travel reimbursement—constitutes a kickback to the patient that indirectly benefits the prescribing physician by ensuring patient adherence to the manufacturer's drug. This theory relies on the "remuneration to any person" language in the AKS, which the government interprets as covering payments made to patients that have the effect of inducing the patient to choose a particular provider or drug. The task force has issued subpoenas to at least 12 major pharmaceutical manufacturers seeking all records related to PAPs, including internal communications about the programs' impact on prescribing patterns, patient adherence rates, and market share. The government's theory is that manufacturers use PAPs as a marketing tool to maintain high prices for their drugs while shielding patients from cost-sharing, thereby eliminating the price sensitivity that would otherwise drive patients to lower-cost alternatives. This enforcement theory directly conflicts with the statutory framework of the Medicare Part D program, which requires plans to cover drugs and permits manufacturers to offer patient assistance under certain conditions specified in 42 C.F.R. § 423.560.

Defense strategies for PODs and PAP cases must focus on the absence of a causal connection between the alleged remuneration and any specific referral decision. For PODs, the defense should emphasize that the physician's ownership interest was acquired at fair market value, that distributions are proportional to ownership percentage and not to referral volume, and that the entity treats all patients equally regardless of whether they are referred by a physician-owner. Expert testimony from valuation specialists and health economists is essential to demonstrate that the physician's return on investment is consistent with comparable passive investments and does not exceed market rates. For PAP cases, the defense should argue that the patient assistance is provided without regard to the patient's choice of provider or drug, that the assistance is means-tested to ensure it goes only to financially needy patients, and that the manufacturer has no mechanism to track whether assisted patients fill prescriptions for the manufacturer's drug versus a competitor's drug. The Supreme Court's decision in United States ex rel. Polansky v. Executive Health Resources, which addressed the government's ability to dismiss qui tam actions, also provides a procedural avenue for challenging task force overreach by arguing that the government's enforcement theories are inconsistent with the statutory purpose of the AKS and the FCA.

Frequently Asked Questions

Q: Does the new task force's strict liability interpretation of the Anti-Kickback Statute mean that any technical compliance error automatically results in False Claims Act liability?
A: In practice, yes, but the law is not settled. The task force has adopted an aggressive interpretation of 42 U.S.C. § 1320a-7b(g) that any claim "resulting from" an AKS violation is automatically false under the FCA, even if the defendant had no intent to defraud. However, the Supreme Court's materiality standard from United States ex rel. Escobar v. Universal Health Services requires the government to prove that the AKS violation was material to the government's payment decision. Defense counsel should challenge the government's strict liability theory by arguing that minor technical deviations from safe harbor requirements do not render claims false, particularly where the compensation was fair market value and the services were actually performed. The task force's position has been rejected by at least one district court in the Northern District of Illinois, and appeals are pending in several circuits.

Q: How should providers respond if they receive simultaneous grand jury subpoenas and civil investigative demands from the task force?
A: Immediate retention of experienced federal criminal defense counsel is critical because the 72-hour window for initial response is the most dangerous period. Do not produce documents without counsel reviewing them for privilege, work product, and responsiveness. The task force expects providers to waive the attorney-client privilege by producing internal compliance reviews, but you should resist this pressure and assert privilege claims where appropriate. Consider filing a motion to quash or for a protective order under Federal Rule of Criminal Procedure 17(c)(2) if the subpoenas are overbroad or unduly burdensome. Simultaneously, engage a health care regulatory attorney to begin parallel negotiations with the Civil Division, because the task force's integrated structure means that civil settlement discussions can influence criminal charging decisions. Finally, preserve all documents related to the arrangements under investigation, including emails, meeting minutes, and financial analyses, because spoliation of evidence can result in adverse inference instructions and independent criminal charges under 18 U.S.C. § 1519.

If you or your organization is facing a task force investigation, subpoena, or civil investigative demand related to False Claims Act or Anti-Kickback Statute allegations, the window for strategic response is narrow and the stakes are existential. With treble damages, per-claim penalties of up to $27,018 per false claim, mandatory exclusion from federal health programs, and potential criminal incarceration, you cannot afford to treat this as a routine regulatory matter. I invite you to contact my office for a confidential consultation, during which we will conduct an immediate threat assessment, evaluate your exposure under the task force's enforcement theories, and develop a coordinated defense strategy that addresses criminal, civil, and administrative risks in a unified framework. My 25 years as a federal prosecutor gave me